Table 5. Distribution of clinical features of patients used in circulating DNA analyses.
| Characteristics | Recurrent Patients | Non-Recurrent Patients | |||
|---|---|---|---|---|---|
| n=37 | (%) | n=175 | (%) | ||
| Age | Mean | 55.5 | 56.8 | ||
| Median | 55 | 55 | |||
| Range | 32-80 | 28-81 | |||
| Menopausal status | Pre | 12 | (32.4%) | 58 | (33.1%) |
| Peri | 1 | (2.7%) | 10 | (5.7%) | |
| Post | 24 | (64.8%) | 105 | (60%) | |
| NA | 0 | (0.0%) | 2 | (1.1%) | |
| Histology | IDC | 30 | (81.1%) | 151 | (86.3%) |
| ILC | 4 | (10.8%) | 18 | (10.3%) | |
| DCIS | 1 | (2.7%) | 5 | (2.9%) | |
| NA | 2 | (5.4%) | 1 | (2.7%) | |
| Grading | 1 | 1 | (2.7%) | 21 | (14.3%) |
| 2 | 18 | (48.6%) | 111 | (60.9%) | |
| 3 | 17 | (45.9%) | 34 | (18.0%) | |
| NA | 1 | (2.7%) | 9 | (6.8%) | |
| Focality | Uni | 29 | (78.4%) | 135 | (75.2%) |
| Multi | 7 | (18.9%) | 39 | (24.1%) | |
| NA | 1 | (2.7%) | 1 | (0.8%) | |
| Tumor Size | Tis | 2 | (5.4%) | 5 | (2.8%) |
| T0 | 2 | (5.4%) | 15 | (8.6%) | |
| T1 | 11 | (29.7%) | 76 | (43.4%) | |
| T2 | 14 | (37.8%) | 67 | (38.3%) | |
| T3 | 4 | (10.8%) | 9 | (5.1%) | |
| T4 | 4 | (10.8%) | 2 | (5.4%) | |
| Lymph node | N0 | 21 | (56.8%) | 121 | (69.1%) |
| N1 | 10 | (27.0%) | 33 | (18.9%) | |
| N2 | 1 | (2.7%) | 12 | (6.9%) | |
| N3 | 5 | (13.5%) | 9 | (5.1%) | |
| ER status | Positive | 25 | (67.6%) | 150 | (87.2%) |
| Negative | 12 | (32.4%) | 23 | (11.3%) | |
| NA | 0 | (0.0%) | 2 | (1.5%) | |
| PR Status | Positive | 25 | (67.6%) | 137 | (82.0%) |
| Negative | 12 | (32.4%) | 36 | (16.5%) | |
| NA | 0 | (0.0%) | 2 | (1.5%) | |
| HER2 Status | Positive | 4 | (10.8%) | 23 | (3.8%) |
| Negative | 32 | (86.5%) | 146 | (91.7%) | |
| NA | 1 | (2.7%) | 6 | (4.5%) | |
| p53 Score | 0-1 | 15 | (40.5%) | 54 | (30.9%) |
| 2-10 | 10 | (27.0%) | 54 | (30.9%) | |
| > 10 | 6 | (16.2%) | 34 | (19.4%) | |
| NA | 6 | (16.2%) | 33 | (18.9%) | |
| Ki67 Score | 1-10 | 6 | (16.2%) | 79 | (45.1%) |
| 11-20 | 8 | (21.6%) | 33 | (18.9%) | |
| 21-50 | 11 | (30.4%) | 33 | (18.9%) | |
| > 50 | 10 | (29.7%) | 22 | (12.6%) | |
| NA | 2 | (5.4%) | 8 | (4.6%) | |
| Chemo_therapy | Yes | 28 | (75.7%) | 104 | (57.9%) |
| No | 9 | (24.3%) | 71 | (42.1%) | |
| Radio_therapy | Yes | 30 | (81.1%) | 149 | (86.5%) |
| No | 7 | (18.9%) | 26 | (13.5%) | |
| Endocrine_therapy | Yes | 24 | (64.9%) | 117 | (63.2%) |
| No | 13 | (35.1%) | 58 | (36.8%) | |
| Surgical Type | BCT | 25 | (67.6%) | 132 | (78.9%) |
| Mastectomy | 10 | (32.4%) | 42 | (21.1%) | |
| NA | 2 | (32.4%) | 1 | (21.1%) | |
| Distant Recurrence No. | 27 | lung | 8 | ||
| liver | 13 | ||||
| bone | 20 | ||||
| other | 15 | ||||
| Local-regional Recurrence No. | 10 | local | 7 | ||
| regional | 3 | ||||
Abbreviations: ER - oestrogen receptor, PR - progesterone receptor, HER2 - human epidermal growth factor 2, T - tumor size, N - lymph node status, BCT - breast conserving therapy.